Theravance and Janssen to Advance TD-1473 for Treatment of Inflammatory Bowel Diseases

Theravance and Janssen to Advance TD-1473 for Treatment of Inflammatory Bowel Diseases
Theravance Biopharma Ireland Limited, a Theravance Biopharma subsidiary, and Janssen Biotech have joined forces to develop and commercialize the investigational therapy TD-1473 as a treatment for inflammatory bowel diseases (IBDs) such as Crohn’s disease and ulcerative colitis. TD-1473 is an orally administered, highly specific inhibitor of the Janus kinase (JAK) family of enzymes, which play a critical role in inflammation. JAK inhibitors are currently approved to treat rheumatoid arthritis (RA) and myelofibrosis. They have also demonstrated some benefit for patients with ulcerative colitis. However, these products are known to have certain side effects associated with their systemic exposure. TD-1473 has a specific type of activity that is restricted to the intestinal tract, which prevents the risk of systemic exposure and unwanted side effects. Under the agreement, Theravance will receive $100 million upfront from
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *